Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Year-over-year gross profit growth rate
Percentile
P41
Within normal range
vs 5Y Ago
-9.5x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -7.46% |
| Q3 2025 | -6.64% |
| Q2 2025 | 5.72% |
| Q1 2025 | 90.23% |
| Q4 2024 | 12.31% |
| Q3 2024 | -34.18% |
| Q2 2024 | 18.26% |
| Q1 2024 | -20.35% |
| Q4 2023 | 56.14% |
| Q3 2023 | -38.51% |
| Q2 2023 | 97.27% |
| Q1 2023 | -66.00% |
| Q4 2022 | 458.56% |
| Q3 2022 | -90.32% |
| Q2 2022 | 255.02% |
| Q1 2022 | 16.96% |
| Q4 2021 | -20.90% |
| Q3 2021 | 7749.76% |
| Q2 2021 | -97.64% |
| Q1 2021 | -40.76% |
| Q4 2020 | 0.79% |
| Q3 2020 | 135.09% |
| Q2 2020 | -239.02% |
| Q1 2020 | 2.09% |
| Q4 2019 | 10.81% |
| Q3 2019 | -14.92% |
| Q2 2019 | 52.46% |
| Q1 2019 | -20.62% |
| Q4 2018 | 398.68% |
| Q3 2018 | 24.47% |
| Q2 2018 | -49.44% |
| Q1 2018 | -181.73% |
| Q4 2017 | 208.64% |
| Q3 2017 | -14.42% |
| Q2 2017 | 61.13% |
| Q1 2017 | -22.83% |
| Q4 2016 | -2.12% |
| Q3 2016 | -1.17% |
| Q2 2016 | -52.59% |
| Q1 2016 | 52.96% |